
Revumenib Gains FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML
The FDA has granted priority review to the supplemental new drug application (sNDA) of revumenib (Revuforj), an oral, first-in-class Menin inhibitor, for the treatment of relapsed or refractory (R/R) NPM1-mutant (mNPM1) acute myeloid leukemia (AML).1 …